Wells Fargo & Company MN boosted its holdings in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 28.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 172,897 shares of the biopharmaceutical company’s stock after purchasing an additional 37,826 shares during the quarter. Wells Fargo & Company MN’s holdings in Alder BioPharmaceuticals were worth $2,117,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Quantitative Systematic Strategies LLC purchased a new stake in Alder BioPharmaceuticals during the 3rd quarter worth approximately $132,000. Legal & General Group Plc increased its holdings in Alder BioPharmaceuticals by 2.6% during the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 400 shares during the last quarter. SG Americas Securities LLC increased its holdings in Alder BioPharmaceuticals by 109.4% during the 2nd quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 8,140 shares during the last quarter. Voya Investment Management LLC increased its holdings in Alder BioPharmaceuticals by 8.4% during the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 1,734 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in Alder BioPharmaceuticals by 13.4% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 30,520 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 3,616 shares during the last quarter. Institutional investors own 96.80% of the company’s stock.

Several research firms have issued reports on ALDR. Cowen began coverage on Alder BioPharmaceuticals in a report on Tuesday, September 26th. They set an “outperform” rating and a $20.00 price objective on the stock. BidaskClub upgraded Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research downgraded Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. BMO Capital Markets boosted their price target on Alder BioPharmaceuticals to $26.00 and gave the company an “outperform” rating in a report on Tuesday, January 9th. Finally, Mizuho reiterated a “buy” rating and issued a $29.00 price target (down from $32.00) on shares of Alder BioPharmaceuticals in a report on Tuesday, January 9th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.93.

Alder BioPharmaceuticals, Inc. (ALDR) opened at $16.90 on Wednesday. The company has a market capitalization of $1,140.00, a price-to-earnings ratio of -3.15 and a beta of 2.48. Alder BioPharmaceuticals, Inc. has a 52 week low of $8.60 and a 52 week high of $25.45.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the company earned ($0.70) EPS. sell-side analysts forecast that Alder BioPharmaceuticals, Inc. will post -5.14 EPS for the current year.

In related news, insider Mark James Litton sold 16,519 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the completion of the transaction, the insider now directly owns 116,451 shares in the company, valued at approximately $1,257,670.80. The sale was disclosed in a document filed with the SEC, which is available through this link. 10.60% of the stock is owned by corporate insiders.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/17/wells-fargo-company-mn-has-2-12-million-holdings-in-alder-biopharmaceuticals-inc-aldr.html.

Alder BioPharmaceuticals Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Stock Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related stocks with our FREE daily email newsletter.